TheBioTechReview

Therapeutics

Exploring the latest in Therapeutics.

Beyond the Clinical Hold: How FDA's Liver Safety Request for Lilly's Obesity Pill Reveals Deeper Industry Challenges
Therapeutics

Beyond the Clinical Hold: How FDA's Liver Safety Request for Lilly's Obesity Pill Reveals Deeper Industry Challenges

Beyond the $108M: Why Terremoto's AKT Bet Signals a New Era in Precision Oncology
Therapeutics

Beyond the $108M: Why Terremoto's AKT Bet Signals a New Era in Precision Oncology

Beyond the $1.2B Deal: How UCB's Neurona Acquisition Signals a Paradigm Shift in Epilepsy Treatment
Therapeutics

Beyond the $1.2B Deal: How UCB's Neurona Acquisition Signals a Paradigm Shift in Epilepsy Treatment

Beyond the Deal: How Eli Lilly's CrossBridge Bio Acquisition Reveals the New ADC Arms Race
Therapeutics

Beyond the Deal: How Eli Lilly's CrossBridge Bio Acquisition Reveals the New ADC Arms Race

Beyond Stelara: How Johnson & Johnson's Q1 2026 Reveals a Strategic Pivot in Pharma's Post-Blockbuster Era
Therapeutics

Beyond Stelara: How Johnson & Johnson's Q1 2026 Reveals a Strategic Pivot in Pharma's Post-Blockbuster Era

Beyond the Rash: The Hidden Design Flaws Dooming Dermatology Drug Trials and How to Fix Them
Therapeutics

Beyond the Rash: The Hidden Design Flaws Dooming Dermatology Drug Trials and How to Fix Them